Table 2

Retrospective observational studies on cardiac sarcoidosis treatment

ReferenceYearnTreatmentLV functionHeart blockVTInclusion criteriaComments
Jefic et alw47200921Prednisone 50 mg dailyNRNRNo effectSustained VTSteroids appear to have been ineffective in all
Chiu et al21200543Prednisone 60 mg alternating daysImproved EF in group B (EF 30–55%)NRNR
  • Group A = normal LV

  • Group B = EF 30–55%

  • Group C = EF <30%

Yazaki et al10200175All patients received steroids (variable doses)NRNRNR
  • All patients received steroids

  • No difference in outcomes between high and low dose steroids

Kato et al22200320
  • 7 received steroids

  • 13 did not receive steroids

See comments↓ HB
  • ↓ VT

  • burden

AV block
  • EF unchanged in 7/7 treated group, major decline in 9/13 untreated group

  • VT in 1/7 treated group, VT in 8/13 untreated group

  • AV block resolved in 4/7 treated, 0/13 untreated

Banba et al920079Steroids for positive cardiac gallium scansNRYesNo changeAV block or VTAV block resolved in 5/9 treated with steroids, no change in PVC count pre-/post-steroid
Yodogawa et alw38201131Prednisone 30 mg daily, tapered over 6 months to maintenance dose of 10 mg dailyAverage LVEF 52±13% in 17; 26±5% in 14 patientsNR↓ NSVT and PVC burden
  • NSVT

  • PVC count >300/day

↓ VT/PVC burden only in 17 patients with preserved LVEF. No effect in patients with LV dysfunction
  • AV, atrioventricular; EF, ejection fraction; HB, heart block; LV, left ventricle; LVEF, left ventricular ejection fraction; NR, not reported; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular contraction; VT, ventricular tachycardia.